|
Powered by Cell Signaling Technology |
Site Information |
---|
KNAREAHsQIEKRRR SwissProt Entrez-Gene |
Blast this site against: NCBI SwissProt PDB |
Site Group ID: 3638466 |
Associated spectra: 1 CST |
In vivo Characterization | |
---|---|
Methods used to characterize site in vivo: | |
Disease tissue studied: | |
Relevant cell line - cell type - tissue: |
Downstream Regulation | |
---|---|
Effects of modification on BMAL1: | |
Effects of modification on biological processes: | |
Inhibit interaction with: |
References | |
---|---|
Wang D, et al. (2023) Identification and characterization of the CDK1-BMAL1-UHRF1 pathway driving tumor progression. iScience 26, 106544
37123229 Curated Info |
|
Wang Z, Wu Y, Li L, Su XD (2013) Intermolecular recognition revealed by the complex structure of human CLOCK-BMAL1 basic helix-loop-helix domains with E-box DNA. Cell Res 23, 213-24
23229515 Curated Info |
|
Stokes M (2006) CST Curation Set: 1955; Year: 2006; Biosample1/Treatment/Isotope: cell line, M059K/normal/L, Biosample2/Treatment/Isotope: cell line, M059K/UV/H; Disease: glioblastoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info |